Form 8-K Revance Therapeutics, For: Oct 15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- US stock futures rise on tech rebound before Nvidia, inflation tests
- Oil hits one-week low as investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- Six Flags to move headquarters from Charlotte to Arlington, Texas
Revance Therapeutic (RVNC) PT Lowered to $25 at Needham & Company
October 18, 2021 6:41 AM EDTNeedham & Company analyst Serge Belanger lowered the price target on Revance Therapeutic (NASDAQ: RVNC) to $25.00 (from $45.00) while maintaining a Buy rating.
The analyst commented, "FDA issued a CRL for the Daxi BLA due to deficiencies related to the FDA's inspection of the Revance... More
